FDA approves Tenapanor for chronic kidney disease

FDA approves Tenapanor for chronic kidney disease

The FDA approved tenapanor (Xphozah; Ardelyx, Inc.), making it the first and only phosphate absorption inhibitor approved to reduce serum phosphorus in adults with chronic kidney disease (CKD). Hemodialysis as an adjunctive therapy in patients with chronic kidney disease (CKD). who do not respond to phosphate binders or who do not tolerate any dose of … Read more